Study Lead I
McKesson Corporation | |
United States, Tennessee | |
Apr 25, 2026 | |
|
It's More Than a Career, It's a Mission. Our people are the foundation of our success. By joining our growing team at Sarah Cannon Research Institute (SCRI), a subsidiary of McKesson, you will have the opportunity to become part of one of the largest community-based cancer programs to advance oncology treatments and improve outcomes for cancer patients across the globe. We look for mission-driven candidates who have a desire to advance the fight against cancer and make a difference in the lives of patients diagnosed with cancer every day. Our Mission People who live with cancer - those who work to prevent it, fight it, and survive it - are at the heart of every decision we make. Bringing the most innovative medical minds together with the most passionate caregivers in their communities, we are transforming care and personalizing treatment. Through clinical excellence and cutting-edge research, SCRI is redefining cancer care around the world. The Study Lead serves as the primary responsible party and point of contact during clinical research trial feasibility, clinical operations review, and document collection up until the point of site selection. The Study Lead is expected to be an experienced and fully competent team member who is able to complete role independently or with minimal supervision. The Study Lead provides resolutions to a diverse range of complex problems by working with sponsors/CRO and other internal stakeholders to expedite the Lead Management process. Additionally, the Study Lead will work with clinical operations staff and other resources to assess site capabilities and fill out feasibility questionnaires on behalf of SCRI strategic sites. The Study Lead will coordinate with sponsors/CRO and internal teams to obtain all essential documents that are required for study activation and will present during operational review meetings. Duties and Responsibilities: Duties include but are not limited to:
Mandatory: The following are mandatory expectations of all SCRI employees.
Minimum Qualifications:
Preferred Qualifications:
Interested candidates should submit their application through https://www.scri.com/careers/. Applications will be accepted through May 3, 2026. Please ensure all required materials are included as outlined in the posting. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. It has conducted more than 850 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA in the past decade. SCRI's research network brings together more than 1,300 physicians who are enrolling patients into clinical trials at more than 200 locations in 20+ states across the U.S. Please click here to learn more about our research offerings. McKesson has become aware of online recruiting-related scams in which individuals who are not affiliated with or authorized by McKesson are using McKesson's (or affiliated entities, like CoverMyMeds or RxCrossroads) name in fraudulent emails, job postings or social media messages. In light of these scams, please bear the following in mind: McKesson Talent Advisors do not communicate with candidates via online chatrooms or using email accounts such as Gmail or Hotmail. Note that McKesson does rely on a virtual assistant (Gia) for certain recruiting-related communications with candidates. McKesson job postings are posted on our career site: careers.mckesson.com. We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. | |
Apr 25, 2026